- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02970162
Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS)
A Phase 3, Double-Blind, Placebo-controlled, Randomized, Parallel-Group Study to Evaluate the Efficacy and Safety of Amifampridine Phosphate in Patients With Lambert-Eaton Myasthenic Syndrome
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This was a randomized (1:1), double-blind, placebo-controlled, parallel-group, withdrawal study designed to evaluate the efficacy and safety of amifampridine phosphate in patients diagnosed with LEMS. The study was planned to include approximately 28 male and female patients.
Prior to the study, patients were receiving unblinded treatment in the expanded access program (EAP-001). Patients had to be on a stable dose and frequency of amifampridine phosphate for at least 1 week prior to randomization into LMS-003. Screening and randomization (Day 0) may have been into a single visit.
Patients who met eligibility criteria were randomized 1:1 to amifampridine phosphate (at the patient's optimal dose) or placebo on Day 0.
Baseline assessments were obtained on Study Day 0, while the patient has been on open-label amifampridine phosphate and in relationship to the usual dosing schedule. Patients took blinded study medication on Day 1 through Day 3. On Day 4, a dose of blinded study medication was administered by the site study personnel. This was the same medication that the patient took on Day 1 through Day 3. The assessments listed below were performed following either the second, third, or fourth dose of medication taken on Day 4, and this should be the same dose after which Day 0 assessments were performed. For example, if the patient took their second dose of amifampridine in the clinic on Day 0 and had assessments started 40 minutes later, then on Day 4, that patient should be assessed after taking their second dose of investigational product (IP).
Beginning with the next dose after all Day 0 baseline assessments were completed, the patient received IP through Day 4, with a clinic visit on the last day (Day 4) for assessments.
The planned duration of participation for each patient was up to 12 days, including screening (up to 7 days), Day 0 assessments and randomization, and IP administration (Day 1 through Day 4).
Study Type
Enrollment (Actual)
Phase
- Phase 3
Expanded Access
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90095
- UCLA
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female ≥18 years of age and currently receiving amifampridine phosphate for LEMS.
- Diagnosis of LEMS by antibody testing or electromyography (EMG).
- Completion of anti-cancer treatment at least 3 months (90 days) prior to Screening.
- If receiving peripherally acting cholinesterase inhibitors (e.g. pyridostigmine), a stable dose of cholinesterase inhibitors is required for at least 7 days prior to randomization and throughout the study.
- If receiving permitted oral immunosuppressants (prednisone or other corticosteroid), a stable dose is required for at least 30 days prior to randomization and throughout the study.
- Female patients of childbearing potential must practice an effective, reliable contraceptive regimen during the study.
- Able to perform all study procedures and assessments.
- Willing and able to travel to study site and attend all clinic study visits.
- Willing and able to provide written informed consent.
Exclusion Criteria:
- Clinically significant long corrected QT (QTc) interval on ECG in previous 12 months.
- Seizure disorder.
- Active brain metastases.
- Unable to ambulate.
- Pregnant or lactating females.
- Any other condition which, in the opinion of the Investigator, might interfere with the patient's participation in the study or confound the assessment of the patient.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: amifampridine phosphate
amifampridine phosphate 10 mg (amifampridine equivalent) by mouth, 30 to 80 mg total daily dose, 3 to 4 times per day for 4 days
|
|
Placebo Comparator: placebo (for amifampridine phosphate)
placebo by mouth 3 to 4 times per day for 4 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quantitative Myasthenia Gravis (QMG) Score
Time Frame: change from baseline in QMG score at end of day 4
|
The QMG is a physician-rated test including 13 assessments such as facial strength, swallowing, grip strength, and duration of time that limbs can be maintained in outstretched positions.
Each assessment is graded as 0 (none), 1 (mild), 2 (moderate), or 3 (severe), for a total range of 0-39.
A higher total score indicates a worse outcome.
|
change from baseline in QMG score at end of day 4
|
Subject Global Impression (SGI) Score
Time Frame: change from baseline in SGI score at end of day 4
|
The SGI is a 7-point scale on which the patient rates their global impression of the effects of a study treatment (1=terrible to 7=delighted).
The SGI was assessed by the patient or the patient's parent/guardian/caregiver if the patient was unable to complete the SGI.
The SGI has demonstrated concordance with the physician's assessment of improvement.
|
change from baseline in SGI score at end of day 4
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Clinician's Global Impression of Improvement (CGI-I) at Day 4 Compared to Baseline
Time Frame: change from baseline in CGI-I score at end of day 4
|
The CGI-I captures the Investigator's global impression of the patient's improvement or worsening from baseline status.
The 7-point scale is scored by the Investigator based on changes in symptoms, behavior, and functional abilities.
Each symptom is rated as 1 (very much improved), 2 (much improved), 3 (minimally improved), 4 (no change), 5 (minimally worse), 6 (much worse), or 7 (very much worse).
The total score can range from 0 to 49.
A higher score indicates a worse outcome.
|
change from baseline in CGI-I score at end of day 4
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Triple Timed Up and Go Walk Test (3TUG)
Time Frame: change from baseline in 3TUG at end of day 4
|
The 3TUG is a functional mobility test that requires a patient to stand up from a straight-backed armchair, walk 3 meters, turn around, walk back, and sit down in the chair.
A modification of this is where the individual performs the test 3 times without pause, and the measurement is the average time required to complete each of the 3 repetitions.
Based upon literature reports that a significant change in gait for a similar walk-test is an increase in time of more than 20%, this has been incorporated into the endpoint.
|
change from baseline in 3TUG at end of day 4
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Perry Shieh, MD, PhD, University of California, Los Angeles
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Immune System Diseases
- Neoplasms
- Autoimmune Diseases of the Nervous System
- Autoimmune Diseases
- Neoplasms by Site
- Disease
- Neuromuscular Diseases
- Neurodegenerative Diseases
- Nervous System Neoplasms
- Paraneoplastic Syndromes, Nervous System
- Paraneoplastic Syndromes
- Neuromuscular Junction Diseases
- Myasthenia Gravis
- Syndrome
- Lambert-Eaton Myasthenic Syndrome
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Membrane Transport Modulators
- Neuromuscular Agents
- Potassium Channel Blockers
- Amifampridine
Other Study ID Numbers
- LMS-003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lambert-Eaton Myasthenic Syndrome
-
David P. Richman, MDJacobus PharmaceuticalNo longer available
-
University of Colorado, DenverApproved for marketingLambert Eaton Myasthenic SyndromeUnited States
-
Jacobus PharmaceuticalCompletedLambert-Eaton Myasthenic Syndrome | Eaton-Lambert Myasthenic SyndromeUnited States
-
Catalyst Pharmaceuticals, Inc.CompletedA Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)Lambert Eaton Myasthenic SyndromeUnited States, Spain, Serbia, Russian Federation, Hungary, France, Germany, Poland
-
Louis H. Weimer, MDNo longer availableLambert Eaton Myasthenic Syndrome (LEMS)United States
-
Oregon Health and Science UniversityJacobus PharmaceuticalNo longer availableLambert-Eaton Myasthenic Syndrome (LEMS) | Congenital Myasthenia (CM)United States
-
argenxRecruitingCongenital Myasthenic SyndromeUnited States, Canada, France
-
Catalyst Pharmaceuticals, Inc.CompletedMyasthenic Syndromes, CongenitalUnited States
-
Ricardo MaselliCatalyst Pharmaceuticals, Inc.No longer availableCongenital Myasthenic SyndromeUnited States
-
Mayo ClinicCompletedCongenital Myasthenic SyndromeUnited States
Clinical Trials on Placebo Oral Tablet
-
EstetraICON Clinical ResearchCompletedVasomotor Symptoms | Menopausal SymptomsUnited States, Canada
-
EicOsis Human Health Inc.RecruitingHealthy SubjectsNew Zealand
-
Harmony Biosciences, LLCActive, not recruitingMyotonic Dystrophy 1 | Excessive Daytime SleepinessUnited States, Canada
-
Syntrix Biosystems, Inc.National Institute on Drug Abuse (NIDA); DF/Net ResearchCompletedDiabetic Neuropathies | Neuropathic Pain | Pain, ChronicUnited States
-
University of OxfordNovo Nordisk A/SRecruitingDiabetes Mellitus, Type 2United Kingdom
-
Fulcrum TherapeuticsTerminated
-
EicOsis Human Health Inc.CompletedHealthy AdultsUnited States
-
The Mind Research NetworkTerminatedSmoking Cessation | Tobacco Use DisorderUnited States
-
Cara Therapeutics, Inc.CompletedChronic Kidney Diseases | PruritusUnited States
-
Sunshine Lake Pharma Co., Ltd.CompletedChronic Hepatitis CChina